Phenacetin

As a classic and long-standing antipyretic and analgesic drug, phenacetin acts on the thermoregulatory center of the hypothalamus and inhibits the synthesis and release of prostaglandins to exert antipyretic effects and relieve mild to moderate pain. It was once widely used for the symptomatic treatment of headache, neuralgia, arthralgia and other symptoms. Due to the risk of adverse reactions such as potential nephrotoxicity and hemolytic anemia with long-term use, it is rarely used alone in clinical practice at present, and is mostly used as one of the components of compound preparations in combination with aspirin, caffeine and other ingredients to relieve cold, fever and pain. The applicable population should strictly follow the doctor's advice to evaluate the benefits and risks of medication.

The global market size of phenacetin API is relatively small, with an annual demand stable at the level of hundreds of tons. Affected by the popularization of alternative drugs and restrictions on clinical use, the market size has not increased significantly in recent years, and the overall supply and demand are in a balanced state. Domestic manufacturers are mainly small and medium-sized API enterprises, with low industry concentration. The products are mainly supplied to downstream compound preparation production and export demand, and there is no relevant record of centralized procurement yet.

The original research enterprise of phenacetin is Bayer AG in Germany. It was initially marketed in the form of compound preparations, with no separate original research trade name, and the core compound patent expired in the middle of the last century. At present, the main dosage form in circulation on the market is compound tablets, and single-agent preparations have been withdrawn from the market in many countries. This variety is not included in the domestic reference preparation catalogue. As of September 2025, there is no valid under-review or publicized Class A registration number of phenacetin API on the CDE API registration platform. There is also no single-agent preparation approved for marketing in China, and only a small number of compound preparations containing this ingredient have been approved. (Data as of September 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of phenacetin impurity reference standards, which can meet the needs of impurity qualitative and quantitative research in the process of API production and preparation R&D. Most products are in stock. Orders placed before 16:00 can be shipped on the same day. The products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and fully meet the use standards of pharmaceutical enterprises in registration and declaration and quality control scenarios.